Literature DB >> 24224781

Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection.

A Majid1, J McAninch, D J Morgan, S S El Kamary, M Zhan, L Kapelusznik, R Talwani.   

Abstract

In this real-world cohort, 49% of patients stopped boceprevir-based hepatitis C therapy early, with only 20% stopping due to treatment futility. Having more comorbidities was significantly associated with early discontinuation. Tolerability of boceprevir-based regimens may be substantially worse than reported in clinical trials, particularly for patients with comorbidities.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  adverse events; boceprevir; discontinuation; hepatitis C; treatment

Mesh：

Substances：

Year:  2013        PMID： 24224781     DOI： 10.1111/jvh.12201

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN： 1352-0504            Impact factor:   3.728


  4 in total

1.  Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C.

Authors:  Shivakumar Narayanan; Kerry Townsend; Thomas Macharia; Adrian Majid; Amy Nelson; Robert R Redfield; Shyam Kottilil; Rohit Talwani; Anu Osinusi
Journal:  Hepatol Int       Date:  2014-09-21       Impact factor: 9.029

2.  Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.

Authors:  N Miotto; L C Mendes; L P Zanaga; E S L Goncales; M S K Lazarini; M N Pedro; F L Goncales; R S B Stucchi; A G Vigani
Journal:  Braz J Med Biol Res       Date:  2016-06-23       Impact factor: 2.590

3.  Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.

Authors:  Floor A C Berden; Robert J de Knegt; Hans Blokzijl; Sjoerd D Kuiken; Karel J L van Erpecum; Sophie B Willemse; Jan den Hollander; Marit G A van Vonderen; Pieter Friederich; Bart van Hoek; Carin M J van Nieuwkerk; Joost P H Drenth; Wietske Kievit
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

4.  Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.

Authors:  Lenyta Oliveira Gomes; Marina Rodrigues Teixeira; Júnior André da Rosa; Alberi Adolfo Feltrin; João Paulo V Rodrigues; Mariane D'Avila Vecchi; Jane Meire M Carneiro; Lúcia de Araújo C B Noblat; Silvana Gama F Chachá; Ana de Lourdes C Martinelli; Leonardo Regis L Pereira; Marysabel Pinto T Silveira; Carine Raquel Blatt; Mareni Rocha Farias
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2018-06-28       Impact factor: 1.846
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.